Literature DB >> 21304508

Prostate cancer: reducing overtreatment: active surveillance in low-risk disease.

Jared M Whitson, Sima P Porten, Peter R Carroll.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21304508     DOI： 10.1038/nrurol.2011.8

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?

Authors:  Peter R Carroll; Jared M Whitson; Matthew R Cooperberg
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?

Authors:  Stacy Loeb; Edward F Vonesh; E Jeffrey Metter; H Ballentine Carter; Peter H Gann; William J Catalona
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

3.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Authors:  Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja
Journal:  Lancet Oncol       Date:  2010-07-02       Impact factor: 41.316

4.  Outcomes of active surveillance for men with intermediate-risk prostate cancer.

Authors:  Matthew R Cooperberg; Janet E Cowan; Joan F Hilton; Adam C Reese; Harras B Zaid; Sima P Porten; Katsuto Shinohara; Maxwell V Meng; Kirsten L Greene; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-11-29       Impact factor: 44.544

5.  Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.

Authors:  Julia H Hayes; Daniel A Ollendorf; Steven D Pearson; Michael J Barry; Philip W Kantoff; Susan T Stewart; Vibha Bhatnagar; Christopher J Sweeney; James E Stahl; Pamela M McMahon
Journal:  JAMA       Date:  2010-12-01       Impact factor: 56.272

6.  Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.

Authors:  Neil Fleshner; Leonard G Gomella; Michael S Cookson; Antonio Finelli; Andrew Evans; Samir S Taneja; M Scott Lucia; Eric Wolford; Matthew C Somerville; Roger Rittmaster
Journal:  Contemp Clin Trials       Date:  2007-05-29       Impact factor: 2.226

7.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

8.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

9.  Active surveillance for the management of prostate cancer in a contemporary cohort.

Authors:  Marc A Dall'Era; Badrinath R Konety; Janet E Cowan; Katsuto Shinohara; Frank Stauf; Matthew R Cooperberg; Maxwell V Meng; Christopher J Kane; Nanette Perez; Viraj A Master; Peter R Carroll
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

10.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Authors:  Laurence Klotz; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544
  10 in total
  3 in total

1.  Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience.

Authors:  Uri Lindner; Sangeet Ghai; Paula Spensieri; Eugen Hlasny; Theodorus H Van Der Kwast; Stuart A McCluskey; Masoom A Haider; Walter Kucharczyk; John Trachtenberg
Journal:  Can Urol Assoc J       Date:  2012-12       Impact factor: 1.862

Review 2.  [The importance of pathology in the German prostate cancer study PREFERE].

Authors:  G Kristiansen; M Stöckle; P Albers; H Schmidberger; P Martus; S Wellek; M Härter; R Bussar-Maatz; T Wiegel
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

3.  [Diagnostic histopathology of prostate cancer].

Authors:  G Kristiansen
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.